Description

Intellectual Property (IP) is critical for exits for medical device companies, whether M&A or IPO. Hear from medtech veteran Jeff Mann, who spent 14 years at Boston Scientific, helped sell Cantel Medical to Steris in 2021 (link), and recently completed the spinoff of the diabetes care business (now separate public company named embecta) from Becton, Dickinson and Company on April 1, 2022 (link). 

Medtech patent attorneys David Dykeman and Roman Fayerberg of Greenberg Traurig will lead a discussion on the IP best practices and pitfalls to avoid to build strategic patent portfolios for companies to stay competitive, attract funding or secure a successful exit. Please join the discussion on Tuesday, May 3 at 1 pm.

REGISTER NOW

SPEAKERS

	Jeff Mann Senior Vice President, General Counsel and  Head of Business Development embecta
	David Dykeman Shareholder Greenberg Traurig
	Roman Fayerberg Shareholder Greenberg Traurig